Vera Therapeutics, Inc. ( VERA) reported that in the pivotal ORIGIN 3 trial of TRUTAKNA (atacicept-vymj), an FDA-approved dual BAFF and APRIL inhibitor, it stabilised kidney function and prevented ...

GSK slides 1.82% today to GBX1865.50 despite ongoing progress in oncology and vaccines, with volatility remaining elevated.

Oncology spending may hit $441B by 2029 as growth slows from generics—see 5 underappreciated cancer stocks with catalysts and ...

Find out what came out of the World Conference on Lung Cancer (WCLC) 2026, from late-stage successes and failures to earlier-stage promise.

The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall ...

Most drug licensing deals with China will be safe from rules being drafted by the U.S. Treasury Department, Reuters reports.

GSK (LSE: GSK) has delivered a 58.4% share price return over the past five years, putting real pressure on the question of whether current earnings justify ...

GSK will acquire a Chimagen trispecific T cell engager for multiple myeloma in a deal worth up to $750M. Here's what it means ...

Explore the latest oncology biotech news, from clinical data to fundraising and biotech deals, in our September 2026 roundup.

GSK (NYSE:GSK) is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung ...

GSK plc is returning to China for another oncology asset, agreeing to acquire global rights to a preclinical trispecific T-cell engager from Chimagen Biosciences in a deal worth up to $750 million.

GSK will acquire a trispecific T cell engager for multiple myeloma from Chimagen Biosciences in a deal worth up to $750 ...